Table 2.

Main clinical trials testing molecular targeted agents in mCRPC.

Therapeutic Agent	Clinical Trial N. (Acronym)	Patients Eligibility Criteria	Outcomes
177Lu-PSMA-617	NCT03511664 (VISION)	✓ PSMA+mCRPC ✓ Prior systemic therapy with − androgen receptor inhibitors − taxane chemotherapy	Improvement in overall survival
177Lu-DOTA-rosopatamab	NCT04876651 (PROSTACT)	✓ PSMA+mCRPC ✓ Prior systemic therapy with − one novel androgen axis drug	Ongoing. Data not yet available
225Ac-PSMA-617	NCT04597411 (AcTION)	✓ PSMA+mCRPC	Ongoing. Data not yet available
225Ac-PSMA-I&T	NCT05219500 (TATCIST)	✓ PSMA+mCRPC	Ongoing. Data not yet available
Olaparib	NCT02987543 (PROFOUND)	✓ mCRPC ✓ Mutations in any HR gene ✓ Prior systemic therapy with − abiraterone or enzalutamide	Improvement in overall survival
Rucaparib	NCT02952534 (TRITON2)	✓ mCRPC ✓ BRCA1 or BRCA2 mutations ✓ Prior systemic therapy with − enzalutamide, apalutamide or darolutamide − taxane chemotherapy	Improvement in PSA response rate
	NCT03413995 (TRIUMPH)	✓ Metastatic hormone-sensitive PC ✓ Mutations in any HR gene ✓ No prior androgen deprivation therapy	Ongoing. Data not yet available
	NCT03533946 (ROAR)	✓ Nonmetastatic hormone-sensitive PC ✓ BRCAness * ✓ No prior treatment with PARP inhibitor or platinum based chemotherapy	Ongoing. Data not yet available
Talazoparib	NCT03148795 (TALAPRO-1)	✓ mCRPC ✓ Mutations in any HR gene ✓ Prior systemic therapy with − taxanes − enzalutamide and/or abiraterone acetate/prednisone	Improvement in radiolgical response rate
Ipilimumab	NCT01057810	✓ mCRPC ✓ Prior androgen deprivation therapy	No improvement in overall survival
	NCT00861614	✓ mCRPC ✓ Prior treatment with docetaxel	No improvement in overall survival

* BRCAness: alteration in one or more of the following genes, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, FANCA, NBN, PALB2, RAD51C, RAD51D, RAD51, RAD51B.